Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin –Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study
ConclusionAfter exposure to piperacillin –tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin–tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Dialysis | Drugs & Pharmacology | Insulin | Intensive Care | Study | Urology & Nephrology